Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1886)
Drug Name
AZD-2171
Synonyms
Cediranib; Cediranib (AZD217); Cediranib (AZD2171); Cedirannib; NQU9IPY4K9; Recentin; ZD-2171; 288383-20-0; 4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline; 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; AZD 2171; AZD-2171; AZD2171; CHEMBL491473; NSC-732208; UNII-NQU9IPY4K9
Indication Lung cancer [ICD11: 2C25] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 450.5 Topological Polar Surface Area 72.5
Heavy Atom Count 33 Rotatable Bond Count 8
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
Cross-matching ID
PubChem CID
9933475
PubChem SID
14906490 ; 24208254 ; 26746631 ; 57373832 ; 75977042 ; 96025564 ; 96079499 ; 99432367 ; 103592924 ; 103905340 ; 109692967 ; 123110211 ; 124756936 ; 124766796 ; 125163743 ; 126666991 ; 126730931 ; 129754723 ; 131465106 ; 134221888 ; 134339006 ; 134964400 ; 135194712 ; 135697662 ; 135727476 ; 136368003 ; 136920391 ; 137006068 ; 137275941 ; 139208216 ; 144115802 ; 152258121 ; 152344142 ; 160646960 ; 162011780 ; 162037386 ; 162200059 ; 163884606 ; 164041832 ; 174528685 ; 175426860 ; 177748726 ; 178102292 ; 180190844 ; 185998790 ; 187071991 ; 198958766 ; 198993121 ; 203355740 ; 223384883
ChEBI ID
CHEBI:94782
CAS Number
288383-20-0
TTD Drug ID
D09VMI
Formula
C25H27FN4O3
Canonical SMILES
CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
InChI
1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
InChIKey
XXJWYDDUDKYVKI-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
AZD-2171 metabolite M1 DM002463 N. A. Oxidation - Dioxidation 1 [2]
AZD-2171 metabolite M11 DM002470 N. A. Unclear 1 [2]
AZD-2171 metabolite M2 DM002464 N. A. Unclear 1 [2]
AZD-2171 metabolite M3 DM002465
154572831
Conjugation - N-Glucuronidation 1 [2]
AZD-2171 metabolite M4 DM002466
154572857
Oxidation - N-Oxidation 1 [2]
AZD-2171 metabolite M5 DM002467 N. A. Unclear 1 [2]
AZD-2171 metabolite M7 DM002468
154584962
Unclear 1 [2]
AZD-2171 metabolite M8 DM002469 N. A. Unclear 1 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000336 AZD-2171 AZD-2171 metabolite M1 Oxidation - Dioxidation Unclear [2]
MR000337 AZD-2171 AZD-2171 metabolite M2 Unclear CYP [2]
MR000338 AZD-2171 AZD-2171 metabolite M3 Conjugation - N-Glucuronidation UGT1A4 [2]
MR000339 AZD-2171 AZD-2171 metabolite M4 Oxidation - N-Oxidation FMO3 ... [2]
MR000340 AZD-2171 AZD-2171 metabolite M5 Unclear Unclear [2]
MR000341 AZD-2171 AZD-2171 metabolite M7 Unclear Unclear [2]
MR000342 AZD-2171 AZD-2171 metabolite M8 Unclear Unclear [2]
MR000343 AZD-2171 AZD-2171 metabolite M11 Unclear Unclear [2]
⏷ Show the Full List of 8 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Dimethylaniline oxidase 1 (FMO1) DME0059 Homo sapiens
FMO1_HUMAN
1.14.13.8
[2]
Dimethylaniline oxidase 3 (FMO3) DME0039 Homo sapiens
FMO3_HUMAN
1.14.13.8
[2]
UDP-glucuronosyltransferase 1A4 (UGT1A4) DME0048 Homo sapiens
UD14_HUMAN
2.4.1.17
[2]
References
1 ClinicalTrials.gov (NCT02446600) Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
2 In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos. 2010 Oct;38(10):1688-97.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.